Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus ORAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus ORAVIG.
GRIS-PEG vs ORAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Miconazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
ORAVIG (miconazole) 50 mg buccal tablet applied once daily to the upper gum region (canine fossa) for 14 consecutive days. The tablet is placed with the rounded side against the gum and held in place for 30 seconds to ensure adhesion.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Terminal elimination half-life is approximately 24 hours, supporting once-daily buccal administration for sustained local oropharyngeal concentrations.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Primarily fecal (approximately 52%) with 39% of the dose recovered in urine; less than 0.5% of the dose is excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal